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T cells from antibody-mediated cell lysis through
down-modulation of CD4 and BST2
Tram NQ Pham1, Sabelo Lukhele1, Fadi Hajjar1, Jean-Pierre Routy2 and Éric A Cohen1,3*Abstract
Background: HIV proteins Nef and Vpu down-modulate various host factors to evade immune defenses. Indeed, the
CD4 receptor is down-regulated by Nef and Vpu, whereas virion-tethering BST2 is depleted by Vpu. Antibody-dependent
cell-mediated cytotoxicity (ADCC) is increasingly recognized as a potentially powerful anti-HIV response. Given that
epitopes which are specific for ADCC-competent anti-HIV antibodies are transitionally exposed upon CD4-mediated HIV
entry, we investigated whether by depleting CD4 and BST2, HIV could negatively affect ADCC function.
Results: Using anti-envelope (Env) Abs A32 and 2G12 to trigger ADCC activity, we find that interactions between CD4
and Env within infected cells expose ADCC-targeted epitopes on cell-surface Env molecules, marking infected T cells for
lysis by immune cells. We also provide evidence to show that by cross-linking nascent virions at the plasma membrane,
hence increasing cell-surface Env density, BST2 further enhances the efficiency of this antiviral process. The heightened
susceptibility of T cells infected with a virus lacking Nef and Vpu to ADCC was recapitulated when plasmas from HIV-
infected patients were used as an alternative source of Abs.
Conclusions: Our data unveil a mechanism by which HIV Nef and Vpu function synergistically to protect infected cells
from ADCC and promote viral persistence. These findings also renew the potential practical relevance of ADCC function
in vivo.
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The human immunodeficiency virus (HIV)-type 1 gains
access to its target cells, primarily CD4+ T cells and
macrophages, through the cellular receptor CD4 and co-
receptor CCR5 or CXCR4. The HIV-1 RNA genome en-
codes many proteins including the structural envelope
(Env) and accessory proteins Vpu and Nef. Over the
years, studies have been conducted to decipher how
HIV-1 exploits its viral elements, especially the accessory
proteins, to modulate the host’s fundamental cellular
machineries and responses in order to perpetuate its
existence. Aside from their involvement in altering the
expression of other host factors, Vpu and Nef, along* Correspondence: eric.cohen@ircm.qc.ca
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unless otherwise stated.with Env, can down-regulate CD4, albeit through dis-
tinct mechanisms [1,2]. Indeed, Env and Vpu, which are
expressed late during viral replication, target newly syn-
thesized CD4 molecules in the endoplasmic reticulum
(ER), while the early expressed Nef focuses on CD4
already at the plasma membrane (PM). CD4 down-
modulation by Env [3,4] is mediated through the forma-
tion of CD4-Env complexes in the ER, thus preventing
CD4 trafficking to the cell surface [5], whereas that by
Vpu occurs through CD4 ubiquitination and degradation
via an ER-associated protein degradation (ERAD)-like
mechanism [6,7]. Nef induces endocytosis of cell-surface
CD4 molecules, targeting them for degradation in the
lysosomes [8,9]. This functional redundancy leading to
CD4 depletion is likely to be beneficial to the virus since
it is thought to allow efficient Env trafficking to viral
assembly sites while at the same time preventing super-
infection and premature cell death [2,10]. In addition,
Vpu also down-modulates BST2, a type 1 interferon-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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the cell surface, thus restricting their release from in-
fected cells [11,12].
Antibody-dependent cell-mediated cytotoxicity (ADCC)
is a type of humoral immune response mediated by ef-
fector cells of the innate immune system including natural
killer (NK) cells and monocytes/macrophages [13]. In
ADCC, binding of antibodies (Abs) to antigens present on
target cells occurs through the Fab portion of the Ab, and
leads to target-effector cell engagement via the Fc portion
of the Ab and the Fcγ receptor (FcR) on effector cells.
Binding of antigen-coated IgG to the FcR presumably
causes a release of cytolytic granules and subsequent lysis
of target cells.
Over the past decade, Fc-mediated effector functions
including ADCC have been increasingly recognized as a
potentially powerful host response against HIV-1 infection
and dissemination. Indeed, findings from studies with
HIV-infected patients and simian immunodeficiency virus
(SIV)-infected macaques have implicated ADCC as an im-
mune correlate of viral selection pressure, dampened viral
replication, delayed disease progression, and even infec-
tion immunity [14-17]. Along this line, non-neutralizing
Abs that can mediate FcR-dependent effector functions
against HIV-1 [18-20] are thought to have contributed to
protection in the Thai RV1144 vaccine trial [21]. Further-
more, passive transfer of Abs to macaques established the
critical importance of the Fc portion of IgGs in preventing
infection [22,23]. In summary, these studies underscore
the often underappreciated importance of Fc-mediated ef-
fector responses driven by non-neutralizing Abs in the
overall Ab-mediated protection against HIV-1.
The strength of ADCC function can be influenced by
various host and viral factors. Among these are: (1) FcR
expression levels on effector cells, (2) specificity of the Fab
region, (3) abundance of viral antigens, and (4) accessi-
bility of Abs to their cognate epitopes. In this context, re-
cent studies focused on advancing our understanding of
the nature of Abs that are capable of directing lysis of in-
fected T cells [18,19,24]. As such, much of the research
has been centered on Abs against the HIV-1 Env, since
this protein represents a major viral antigen targeted by
the host’s immune responses. Env is expressed on the sur-
face of infected cells and is incorporated into virions dur-
ing viral assembly. The functional spike of the virion is a
trimeric complex consisting of gp120 and the non-
covalently bound transmembrane gp41 subunit [25]. Env
gp120 is exposed on the virion surface and binds to the
CD4 receptor, whereas gp41 is normally buried within the
viral envelope. Upon binding to CD4, gp120 undergoes se-
quential conformational changes that allow interactions
with one of the primary co-receptors, CXCR4 or CCR5,
which subsequently trigger exposure of the fusogenic
gp41 ectodomain within the Env trimer [26]. Ultimately,the transition of the gp41 ectodomain configuration into a
six-helix bundle results in fusion of the virus to target
cells [26].
Most recently, it has been suggested that the face of
gp120 occluded in the trimeric Env by gp41 is a potent
ADCC target [24]. Indeed, analyses of human monoclonal
Abs that recognize transitional epitopes exposed during
Env-CD4 interactions revealed a strong bias of ADCC-
competent Abs for Cluster A epitopes contained within
this region of gp120 [24]. Among such anti-Env Abs is
A32, which recognizes a discontinuous epitope on the
inner domain of gp120, and has been documented to be
capable of mediating ADCC [18,19]. The A32 epitope,
which is expressed on CD4+ T cells infected in vitro with
transmitted/founder viruses, could trigger efficient ADCC
activity on both virally infected and gp120-coated CD4+ T
cells [18]. More importantly, the A32 Fab fragment could
block the majority of ADCC activity in plasma of HIV-1
infected patients, suggesting that if efficiently accessible,
the A32 epitope is highly recognizable by Abs produced
during HIV infection [18].
In light of the data discussed above, we asked whether
HIV might exploit its natural propensity to down-modulate
CD4 and BST2 to conceal ADCC-targeted epitopes and
shield infected cells from destruction through ADCC.
Here-in, using an in vitro infection system whereby primary
CD4+ T cells are infected with isogenic viruses deficient of
Nef and/or Vpu accessory proteins, we delineate the syner-
gistic contributions of these two HIV proteins to the re-
moval of CD4 and BST2 from the cell surface, thereby
shielding infected T cells from ADCC. With these results,
our study unveils a potential mechanism by which HIV
evades the host’s immune defenses to promote persistence.
Results
Enhanced binding of anti-Env antibodies on CD4+ T cells
infected with viruses deficient of HIV Nef and/or Vpu
To assess the recognition of Env by anti-Env Abs on in-
fected T cells, CD4+ T cells were infected with CCR5-
tropic NL4-3.ADA.IRES.GFP WT virus or its derivatives
lacking Vpu (ΔVpu or U-), Nef (ΔNef or N-) or both
(ΔNefΔVpu or N-U-) and evaluated for Env expression.
For a comparative analysis with A32, we used neutra-
lizing Ab 2G12, which recognizes a discontinuous,
glycan-dependent epitope on the gp120 outer domain
and, as such, is distinct from other neutralizing Abs that
recognize CD4-induced epitopes [27]. To this end, Env
staining by A32 was about 2 to 2.5-fold higher on CEM.
NKR CD4+ T cells infected with the ΔNef or ΔVpu virus
and intriguingly, nearly 8-fold higher on those infected
with the ΔNefΔVpu virus (P < 0.005) (Figure 1A). Not-
ably, the Env staining profile by 2G12 was different with
the ΔVpu virus relative to the ΔNef in that the former













































































































































































































































Figure 1 (See legend on next page.)
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Figure 1 HIV-1 envelope expression profiles on infected CD4+ T cells. CEM.NKR (A and B) or activated primary CD4+ T cells (C and D) were
infected with CCR5-tropic NL4.3.ADA.IRES.GFP wild-type (WT) virus or derivatives lacking Vpu (U-), Nef (N-) or both (N-U-) as detailed in Methods.
Infected cells were analyzed by flow cytometry for Env expression using anti-Env A32 and 2G12 mAbs. (A-D) The left panels depict the extent of
Env staining shown as geo-mean fluorescence intensity (MFI) on gated GFP+ cells from a representative infection. The right panels summarize the
results of (A and B) seven experiments with each dot representing an analysis, and of (C and D) data obtained with primary CD4+ T cells from
four donors. Shown are average fold increase (+/− SEM) in Env staining relative to WT virus-infected cells. Fold increase was determined as the
ratio of MFIs of GFP+ cells infected with different mutants over that for the WT virus. Statistical analysis of data was done using paired Student’s t-tests.
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tion of BST2 to this enhancement. Similar to A32, 2G12
staining was significantly higher with the ΔNefΔVpu
virus (P < 0.0005) (Figure 1B). The Env staining patterns
by A32 and 2G12 were largely similar for primary CD4+
T cells infected with the same viruses, indicating that the
data were not unique to cell lines (Figure 1C and D).
Development and validation of a FACS-based ADCC assay
As shown in Figure 2A, enhanced A32 binding on in-
fected T cells could be blocked by pre-incubating target
cells with the A32 Fab fragment prior to A32 exposure,
demonstrating its specificity. Subsequently, we examined
whether augmented binding of A32 on T cells would
promote their lysis by ADCC.
Our FACS-based ADCC assay makes use of the fact that
infected target cells were GFP-marked, while effector cells
were labelled with a dye, allowing for subsequent gating of
GFP-positive/dye-negative cells at the end of the assay
(Figure 2B). The % cell lysis was determined by [(propor-
tion of GFP+ cells in the absence of effector cells – pro-
portion of GFP+ cells in the presence of effector cells and
test Ab)/proportion of GFP+ cells in the absence of
effector cells] × 100. For the example shown in Figure 2C,
% cell lysis in the presence of A32 was computed to be
[(24.8-15.7)/24.8] × 100 = 36.7%. Similarly, % cell lysis in
the presence of control IgG was 16.5%. Importantly, in all
evaluations, % cell lysis mediated by control IgG was de-
termined simultaneously with test Abs, and used as back-
ground killing to calculate the net Ab (e.g., A32)-specific
cell lysis. For Figure 2C example, the net A32-mediated
lysis was calculated to be 36.7%-16.5% = 20.2%. By the
same formulas, the net A32-mediated lysis in the presence
of the A32 Fab was 6.1% (22.6%-16.5%). The attenuated
ADCC activity, as a result of target cell pre-treatment with
the A32 Fab, was replicated over many analyses using
PBMC from different donors as effectors (Figure 2D). In
addition, Figure 2D also revealed a differential ability by
different PBMC donors to induce ADCC. The observed
variations, which are not uncommon in analyses involving
primary cells, could be due to inter-individual differences
in FcR expression levels or the activation status of effector
cells at the time of PBMC acquisition.
To further validate the assay, we examined the extent
of target cell lysis using different effector:target (ET)ratios, and found that the magnitude of ADCC was ET-
dependent (Figure 2E). Lastly, to determine which im-
mune cell subsets might be responsible for inducing cell
death, we used, as effector cells, total PBMC or PBMC
that had been depleted of NK cells or monocytes/macro-
phages. As shown in Figure 2F, both cell subsets could
elicit ADCC, although NK cells were apparently more
efficient.
Heightened susceptibility of CD4+ T cells infected with
Nef- and Vpu- deficient HIV to A32-mediated ADCC
Using the established ADCC assay, we performed a com-
parative analysis of the susceptibility of T cells infected
with the WT virus or its derivatives to ADCC. Prior to
each analysis, as a qualitative control for the infection, we
performed in parallel Env staining of target cells using
appropriate test Ab(s). Shown in Figure 3A is an example
of A32 staining for the ADCC analysis illustrated in
Figure 3B. Although A32 recognized its epitope compar-
ably well on T cells infected with ΔNef or ΔVpu virus,
those infected with the ΔNef appeared more susceptible
to lysis than their ΔVpu counterparts (Figure 3B). Intri-
guingly, T cells infected with the ΔNefΔVpu virus were
consistently much more prone to lysis than all other target
cells combined (Figure 3C and D). Also, the ADCC acti-
vity against the ΔNefΔVpu virus-infected targets was
clearly not additive of that against ΔNef and ΔVpu virus.
T cells infected with the WT virus were poorly susceptible
to ADCC.
Given that ΔNefΔVpu virus-infected cells were inva-
riably most prone to ADCC, we next compared the ability
of A32 and 2G12 in activating killing of these target cells.
For the example given in Figure 3E, the net Ab-specific
cell lysis for A32 (60.2%-45.0% = 15.2%) was about 4-fold
higher than that for 2G12 (48.7%-45.0% = 3.7%). Similar
observations were made with PBMC from different do-
nors (Figure 3F).
A32-mediated ADCC activity is dependent on cell-surface
CD4 expression and requires CD4-Env interaction
At this point, our data have demonstrated a correlation
between enhanced A32 binding and heightened ADCC
susceptibility. This was most evident in T cells infected
with the ΔNefΔVpu virus (Figures 1 and 3A-D). Given
that the A32 epitope becomes transitionally exposed
targets alone targets + effectors














































































A32 mock:      4.9
A32 N-U-:      55.2
A32 Fab N-U-: 4.6
ET 10 ET 30ET 10ET 30
donor 167 donor 172
24.8%                                20.7%                                15.7%                                  19.2%
Figure 2 Antibody-dependent cellular cytotoxicity assay: development and validation. CEM.NKR cells were infected for 48 h with CCR5-tropic
NL4.3.ADA.IRES.GFP ΔNefΔVpu and analyzed for their susceptibility to ADCC by PBMC under different testing parameters. Target cells were exposed to
either control IgG, A32 or, alternatively, pre-exposed to the A32 Fab prior to the A32 exposure. Env staining was done as described in Figure 1 legend
and ADCC was performed as described in Methods. (A) Evaluation of A32 staining specificity using the A32 Fab. (B) Gating strategy to select
eFlour670-negative, GFP + target cells by flow cytometry. (C) Determination of net Ab-specific cell lysis using gating strategy depicted in (B). The
number shown inside dot plot depicts % of GFP+ cells remaining at the end of assay. Percent of cell lysis was calculated as [(% GFP+ cells in the
absence of effectors -% GFP+ cells in the presence of effectors plus control IgG, A32 or A32 Fab + A32)/% GFP+ cells in the absence of effectors] × 100.
(D) Cell lysis in the absence (A32) or presence of the A32 Fab fragment (A32 Fab + A32). Net Ab-specific cell lysis was obtained following subtraction
of % cell lysis in the presence of IgG from that by either A32 or A32 Fab + A32. Each line represents PBMC-mediated lysis from a donor. (E) Effect of
varying ET ratios (10 or 30) on net Ab-specific cell lysis using A32 as test Ab and IgG as control. Shown are results from two representative donors.
(F) Contributions of different cell subsets to induction of ADCC. Total PBMC or PBMC depleted of monocytes/macrophages (PBMC-Mo) or NK cells
(PBMC-NK) were used as effector cells. A32 was used as test Ab and IgG as control. Histograms represent average net A32-specific lysis +/− SD of four
experiments with five donors.














without effectors with effectors













19.1%                                  10.5%                                      7.6%                                    9.8%    
without effectors with effectors
IgG A32 2G12





























15.4%                               12.1%                               12.0%       
 23.9%                              18.7%                              16.7%    
 10.0%                               7.8%                                  7.5%    








































Figure 3 (See legend on next page.)
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Figure 3 Nef and Vpu reduce susceptibility of infected CD4+ T cells to A32-mediated ADCC. CEM.NKR cells were infected with CCR5-tropic
NL4.3.ADA. IRES.GFP viruses as mentioned in Figure 1 legend. Target cells were incubated with control IgG, A32 or 2G12 and analyzed for susceptibility
to ADCC mediated by PBMC effector cells. Net Ab-specific cell lysis was computed as described in Figure 2 legend. As a qualitative control for infection,
prior to the ADCC evaluation, target cells were also stained for Env expression using anti-Env Abs. (A) Env staining of target cells using A32. (B) An
example of net Ab-specific cell lysis (using A32 as test Ab) from a representative donor (donor 143 in Panel C). (C) Comparative analysis of susceptibility of
different target cells to A32-mediated ADCC. The five sets of numbers indicated on the right hand side of the lines represent five donors. (D) Summary of
net A32-mediated cell lysis from six infections using PBMC from twelve donors as effector cells (each dot represents an individual). (E and F) Susceptibility
of ΔNefΔVpu virus-infected cells to ADCC induced by A32 compared to that by 2G12. Shown in (E) is the result of a representative donor and in (F) is a
summary of three experiments with seven donors, with each line representing data from a given individual. Statistical analysis of data was done using
paired Student’s t-tests.
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both Nef and Vpu down-modulate CD4 within infected
cells, we asked if the strength of ADCC function was re-
lated to CD4 expression. Indeed, CD4 down-modulation
was greatest on WT-virus infected cells (about 75 and
90% on CEM.NKR [Figure 4A] and primary CD4+ T
[Figure 4B] cells, respectively). Similarly, CD4 expression
on ΔNef and ΔNefΔVpu virus-infected cells was reduced
by 50-60% and 25-35%, respectively, highlighting the in-
dividual contributions of Nef and Vpu to CD4 depletion.
Nonetheless, the role of Vpu in CD4 down-regulation
was less evident in the presence of Nef, owing presu-
mably to the distinct mechanisms utilized by the two
proteins to decrease CD4 expression [1,2]. Interestingly,
the use of the ΔNefΔVpu-D368A Env virus, which har-
bours a mutation within the CD4-binding site of gp120
[28], completely prevented CD4 down-regulation, reaf-
firming the role of Env in interacting with CD4 and con-
tributing to its depletion [3-5].
Interestingly, A32 staining on ΔNefΔVpu-D368A Env
virus-infected T cells was significantly less (P < 0.005)
compared to that on their ΔNefΔVpu virus counterparts
(Figure 4C), highlighting the necessity of CD4-Env interac-
tions within infected cells for unmasking the A32 epitope
at the cell surface. In sharp contrast, 2G12 staining was not
affected by the presence of the D368A mutation, suggest-
ing that CD4-Env interactions are dispensable for 2G12
recognition (Figure 4D). Functionally, the reduction in A32
staining on ΔNefΔVpu-D368A Env virus-infected T cells
was correlated with a statistically significant (P < 0.005)
decrease in ADCC activity compared to that with
the ΔNefΔVpu virus (Figure 4E).
BST2 partially contributes to enhanced ADCC activity on
infected T cells
At this point, we clearly demonstrated the necessity of
cell-surface CD4 accumulation and CD4-Env interactions
for the A32 epitope to be exposed. However, the residual
A32 staining and ADCC activity observed with the
ΔNefΔVpu-D368A Env mutant, which were still higher
than that seen with the WT virus (Figure 4C and E),
implied a potential involvement of a CD4-independent
factor. We thus hypothesized that the remaining 3-foldincrease in A32 epitope recognition and ADCC activity
was due to the accumulation of Env-containing virions at
the cell surface arising from the absence of Vpu-mediated
BST2 antagonism. To test this, we depleted BST2 from
CEM.NKR Tcells using a lentivirus-based vector that con-
tains non-targeting (NT) or BST2-targeting (SH) shRNA.
Using this system, BST2 expression was depleted in at
least 95% of the cells (MFI 9.1 on SH cells vs. 80.3 on NT
cells, Figure 5A upper panel), leaving about 5% still dis-
playing BST2 at levels comparable to those on NT cells.
Having said that, BST2 depletion in the 95% of cells was
not complete since low-level BST2 was still detectable
(compare staining of SH cells with pre-immune serum to
that with BST2 Ab: MFI 2.7 vs. 9.1, respectively in
Figure 5A). Of importance, the CD4 level was comparable
between BST2-expressing (i.e., NT) and BST2-depleted
(i.e., SH) cells. To confirm that BST2 depletion would
mediate a change in virus particle release, the cells were
infected with WT or ΔVpu, (U-) virus, and evaluated for
virus particle release (Figure 5B). As expected, the level of
viral release by ΔVpu virus-infected T cells in the NT cell
line was about 25% of that from cells infected with the
WT virus, reaffirming the role of BST2 in tethering virions
at the cell surface (note the accumulation of mature p24
in cell lysates of ΔVpu virus-infected T cells in the upper
left panel of Figure 5B). In contrast, in BST2-depleted
(SH) cells, the release of the Vpu-defective virus was
restored to levels that were largely comparable to that of
the WT virus (right panels, Figure 5B; in this context, cell-
associated p24 levels were similar between WT and ΔVpu
virus-infected T cells). The observed partial restriction in
viral particle release is likely the result of the incomplete
BST2 depletion achieved with this cell line (Figure 5A).
Upon BST2 depletion, we found that Env recognition by
the A32 and 2G12 Abs was differentially reduced in cells
infected with the different viruses (Figure 5C and
Additional file 1: Figure S1). Indeed, A32 staining on
ΔNefΔVpu virus-infected T cells of the SH line was de-
creased by ~30-60% depending on experiments, while that
on the ΔNefΔVpu-D368A Env counterparts, by ~50%.
However, for both NT and SH cells, A32 binding on
ΔNefΔVpu virus-infected T cells remained higher than




























































































































































































Figure 4 (See legend on next page.)
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Figure 4 Heightened susceptibility to A32-mediated ADCC is intimately dependent on CD4 expression and CD4-Env interactions on
target cells. CEM.NKR cells or primary CD4+ T cells were infected with CCR5-tropic NL4.3.ADA.IRES.GFP viruses as mentioned in Figure 1 legend. The
ΔNefΔVpu-D368A Env (N-U-D368A) virus harbours a mutation within the CD4-binding site of Env protein leading to defective CD4-Env interactions.
(A-B) CEM.NKR cells (A) and primary CD4+ T cells (B) were examined by flow cytometry for CD4 expression. The latter was determined based upon
MFI values obtained for gated GFP+ cells. % CD4 down-regulation was calculated as: (MFI of infected cells / MFI of GFP- (uninfected) cells) × 100.
Shown are average % of CD4 down-regulation of (A) a series of experiments (each dot represents an analysis), or (B) five evaluations with five donors.
Error bars indicate SEM. (C-D) CEM.NKR T cells infected with WT, ΔNefΔVpu or ΔNefΔVpu-D368A virus were evaluated for Env expression using A32
(C) and 2G12 (D) Abs as detailed in Figure 1 legend. Env staining was determined based upon the MFI values obtained for gated GFP+ cells. Calculations
of fold increase in Env staining were as described in Figure 1 legend. (E) CEM.NKR T cells were evaluated for their susceptibility to A32-mediated ADCC
as described in Figure 2 legend. Shown are average net cell lyses from four infections. Cell killing was done using PBMC from nine donors as effectors,
with each dot representing an individual. Statistical analysis of data was done using paired Student’s t-tests.
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and BST2 on A32 epitope exposure (Figure 5C, upper
panels). In contrast, while 2G12 recognition was generally
reduced upon BST2 depletion, the staining patterns
between ΔNefΔVpu and ΔNefΔVpu-D368A Env virus-
infected cells were similar for both cell lines. This finding
reaffirmed the data shown in Figure 4D in that Env
staining by 2G12 does not require CD4-Env interactions.
Interestingly, in conditions where BST2 was deple-
ted (Additional file 1: Figure S1) or naturally absent
(Additional file 2: Figure S2), the patterns of A32 and
2G12 staining on ΔVpu virus-infected cells were compar-
able to those on cells infected with the WT virus, implying
that the enhanced Env recognition on BST2-expressing
cells was likely attributed by the virion-tethering effect of
BST2. On this note, analysis of Jurkat T cell lines expres-
sing varying levels of CD4 and/or BST2 clearly revealed
the relative contributions of CD4 and BST2 expression to
the increase in Env staining by A32 and 2G12 in the
context of WT and ΔNef and/or ΔVpu HIV infections
(Additional file 2: Figure S2).
Functionally, we observed no significant decrease in
ADCC activity against NT and SH cells infected with the
ΔNefΔVpu virus (Figure 5D). However, the reduced A32
epitope exposure on ΔNefΔVpu-D368A Env virus-infected
cells in the SH line abolished the “residual” ADCC activity,
suggesting that BST2 most likely contributed to the ADCC
function in ΔNefΔVpu-D368A Env virus-infected NTcells.
Plasmas from HIV-infected individuals induced robust
ADCC activity against T cells infected with the ΔNef and
ΔVpu viruses
To further validate the role of CD4 and BST2 in pro-
moting ADCC in an in vivo relevant setting, we examined
whether plasmas from HIV-infected individuals could
mediate lysis of infected targets in a manner similar to
A32. To this end, we found that the Env recognition pat-
terns by patient plasmas nearly mirrored those by A32
(Figure 6A): the ΔNefΔVpu-virus-infected targets were
most predominantly stained. As with A32, the use of the
ΔNefΔVpu-D368A Env virus reduced the level of Env rec-
ognition, albeit to varying extent (1.5 to 5-fold) dependingupon plasmas. In line with the A32 data, these infected
plasmas elicited the most robust ADCC activity in
ΔNefΔVpu-virus-infected targets (Figure 6B and C).
Intriguingly, we found that for certain plasmas, the dif-
ference in ADCC activity against ΔNefΔVpu D368A Env
and ΔNefΔVpu virus-infected targets was not statistically
significant (compare N-U- to N-U-D368A of Figures 6B
and 6C). Coincidentally, in the cases where this difference
was not achieved (plasmas 1 and 4 shown in Figure 6C)
we also observed a remarkably higher ADCC activity for
the ΔVpu relative to the ΔNef virus implying perhaps a
greater abundance of Abs behaving like 2G12 in these
plasmas. It should however be mentioned that these cha-
racteristics of the plasmas were established post-analysis.
Aside from the differences in the types of anti-Env
Abs that are potentially present, variations in host fac-
tors such as FcR expression levels and phenotype of the
receptor may have also contributed to the kind of ADCC
activity observed (compare plasma 4, donor 142 in
Figure 6B to plasma 4, donors 135 and 137 in Figure 6C).
This being said, these results clearly indicate that Vpu
and Nef protect HIV-infected cells from ADCC-
mediated by antibodies present in plasmas of HIV-
infected individuals.
Discussion
Recent studies have offered insights on the characteristics
of the epitopes on HIV-1 gp120 that are recognized by
ADCC-mediating Abs such as A32 [18,24]. With these re-
sults, there emerges a renewed interest in understanding
not only how Abs targeting CD4-exposed epitopes could
contribute to the overall HIV-induced ADCC response,
but also how the virus might evolve to circumvent this
mode of defence. Our data presented here-in demonstrate
that enhanced exposure of the A32 epitope is intimately
correlated with augmented ADCC activity against infected
T cells. Importantly, the magnitude of epitope recognition
by A32 is invariably dependent on both cell-surface
expression of CD4 and Env and CD4-Env interactions on
infected cells. Lastly, by removing CD4 and BST2 from
the cell surface, HIV Nef and Vpu function individually




















































































































































































Figure 5 (See legend on next page.)
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Figure 5 Dissecting the potential involvement of BST2 in enhancing target cell lysis via ADCC. CEM.NKR CD4+ T cells were transduced
with a lentivirus containing a non-targeting (NT) or a BST2-targeting (SH) shRNA as described in Methods. (A) BST2 and CD4 expression on NT and
SH cells as examined by flow cytometry. Parallel staining with a rabbit PI was used as a control for BST2 staining. Shown next to the overlays are expression
levels in MFI obtained for gated GFP+ infected cells from a representative analysis. (B) NT and SH T cells were infected with WT or ΔVpu (U-) virus and
assessed for HIV-1 viral release efficiency by Western blotting. Mock (M)-infected cells were used as control. Parallel virions and cell lysates were
analyzed for total Gag proteins, GFP and Vpu. The histograms underneath the Western blots depict the average quantifications of the densitometric
signals from two experiments. Virus release was determined to be the ratio of the virion-associated Gag signal (corresponding to the mature p24) over
all cell-associated Gag signals (corresponding to p24 and precursor p55). Within the NT and SH cells, viral release by WT virus was considered to be
100% and that by ΔVpu virus counterparts was expressed as % of the WT. (C-D) NT and SH CD4+ T cells were infected with WT, ΔNefΔVpu (N-U-), or
ΔNefΔVpu-D368A Env (N-U-D368A) virus. Env staining by A32 and 2G12 was analyzed by flow cytometry (C). The histograms depict average fold
increase (+/− SD) in Env recognition relative to WT virus-infected cells in three experiments. In parallel, target cells were evaluated for their susceptibility
to A32-mediated cell lysis by ADCC as detailed in Figure 2 legend (D). Shown are average (+/−SD) net cell lyses by PBMC from six donors. See also
Additional file 1: Figure S1 and Additional file 2: Figure S2.
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Figure 6 The presence of Nef and Vpu efficiently shields HIV-infected T cells from ADCC mediated by plasma from HIV-infected individuals.
CEM.NKR cells were infected with viruses as mentioned in Figure 1 legend. (A) Target cells were stained with plasma samples from an HIV
seronegative person (164HH) or from HIV-infected individuals (different plasmas were color coded). Env expression was determined as described
in Figure 1 legend. (B-C) Target cells incubated with plasmas as described in (A) were analyzed for their susceptibility to ADCC using PBMC as
effector cells. Net Ab-specific cell lysis was computed as described in Figure 2 and obtained following subtraction of background killing of the
same targets induced by the 164 HH plasma. Panel B depicts ADCC activity mediated by patient plasmas, which appeared enriched with A32-like
anti-Env Abs. Panel C illustrates ADCC activity induced by patient plasmas containing A32-like as well as other ADCC-competent anti-Env Abs.
These characteristics of the patient plasmas were established post-analysis. The four sets of numbers indicated on the right hand side of the lines
represent four donors. Data shown are representative of 3 analyses using plasmas from 6 infected individuals and PBMCs from 8 donors. Statistical
analysis of data was done using paired Student’s t-tests.
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accessory proteins that could help protect infected T cells
from ADCC, revealing yet another mechanism of immune
evasion exploited by HIV-1. In fact, the evidence reported
here-in demonstrates that both Vpu and Nef contribute to
the protection of HIV-infected cells from ADCC mediated
by Abs that are present in plasmas of HIV-infected in-
dividuals. This underlies the in vivo relevance of our
findings.
When CD4+ T cells were infected with the ΔNef or the
ΔVpu virus, we observed a moderate increase of 2–3 fold
in A32 binding compared to that on WT virus-infected T
cells. Surprisingly, the A32 epitope recognition was signi-
ficantly higher (8–16 fold) on T cells infected with the
ΔNefΔVpu virus, suggesting a synergistic effect by Nef
and Vpu. Functionally, this enhanced exposure of the A32
epitope led to heightened ADCC-mediated lysis of target
cells, with those infected with the ΔNefΔVpu virus being
most susceptible, and those infected with the ΔNef virus
moderately prone to ADCC. Subsequent analysis of CD4
expression at the surface of infected cells (WT, ΔNef,
ΔVpu and ΔNefΔVpu) revealed a compelling inverse cor-
relation between the extent of CD4 down-modulation and
the degree of cell susceptibility to ADCC. Indeed, the
most potently lysed ΔNefΔVpu virus-infected cells had
only 30% of their CD4 down-regulated, while those mo-
derately susceptible to ADCC (e.g., cells infected with the
ΔNef virus) had their CD4 expression reduced by 50%. In
contrast, when the vast majority of CD4 was depleted
from the cell surface, as in the case of WT or apparently
ΔVpu virus-infected cells, cells were poorly susceptible to
ADCC. Having said that, the effect of Vpu on CD4 down-
regulation may have been masked by that of Nef since
Vpu’s activity was only evident in the context of the
double mutant virus in primary CD4+ T cells and CEM
NKR T cells. On this note, given the spatially separated
and temporally distinct mechanisms exploited by Nef and
Vpu to degrade CD4 [2], it is likely that in the presence of
Nef, the effect of Vpu cannot be adequately quantified
during the 48-hour infection. In turn, this may result in
the seemingly lower susceptibility of ΔVpu virus-infected
targets to A32-mediated ADCC. One possible approach
towards further elucidating the contribution of Nef-
mediated down-regulation of cell-surface CD4 to ADCC
would be to use Nef mutants that are incapable of me-
diating CD4 endocytosis. These evaluations, which are
currently underway, would help corroborate our ADCC
data with the ΔNef virus. Since ADCC is mediated mainly
by NK cells through the Fcγ receptor, it would seem un-
likely that the Vpu-mediated downregulation of NK cell
receptor SLAMF6/NTBA [29] may have contributed to
the lower susceptibility of ΔVpu virus-infected to ADCC.
The accumulation of CD4 at the cell surface was not
sufficient to trigger cell lysis. We found that Env andCD4 interactions were necessary to unmask the A32 epi-
tope since the use of the ΔNefΔVpu-D368A Env virus
led to significantly reduced A32 binding and decreased
ADCC function. In this context, similar findings were
also recently reported by others [30]. On the notion of
CD4-Env interactions, a recent analysis of cryo-EM
structures of virion-associated Env trimer predicted the
occlusion of the ADCC-competent JR4 epitope by gp41,
in the presence of soluble CD4 (N. Gohain et al., 2013,
Keystone Symposia: HIV vaccines, abstract). The cited
study also revealed that JR4, together with other ADCC-
competent Abs recognizing the so-called Cluster A epi-
topes [24], bound poorly to surface Env trimers in the
presence of soluble CD4 but reacted efficiently with
surface-bound virions, lending further support to the
requirement of Env and cell-surface CD4 binding for the
exposure of A32-like epitopes. Taken together, these
findings suggest that CD4 molecules accumulated at the
surface of infected cells would engage cell-surface Env
molecules in a way similar to that when an incoming
virion interacts with the CD4 receptor, through its Env,
to enter a target cell.
Aside from showing the necessity of CD4-Env interac-
tions, our analysis with the ΔNefΔVpu-D368A Env virus
also implicated the involvement of BST2 in Env recogni-
tion, most likely through the retention of virus particles at
the cell surface. Indeed, when BST2 was depleted at the
plasma membrane, the residual ADCC activity against
T cells infected with the ΔNefΔVpu-D368A Env was
essentially abolished. As for the ΔNefΔVpu virus, although
the depletion of BST2 led to a moderate reduction in A32
binding without significantly changing the ADCC func-
tion, we think this could have been due to the incomplete
removal of BST2 from the CEM cells by the shRNA.
BST2 contribution to the enhancementof ADCC function
was strengthened by our findings with plasmas from HIV-
infected individuals. They clearly show that BST2 can
contribute significantly to this process. We are currently
pursuing additional studies using Vpu mutants that are
defective for BST2 binding to further strengthen this
argument. These investigations would complement the
analyses with the Nef mutants that were mentioned in the
previous section and, as such, should provide key insights
into the relative contributions of BST2 and CD4 to CD4-
induced and non CD4-induced epitope-sensitization. At
this juncture, however, the existing data strongly support
the notion that CD4 is a more predominant player in
potentially inducing a conformational change in the Env
and, as such, a more pronounced ADCC function. On a
relevant note, a recent work has postulated a role for
ADCC in the complete protection of macaques previously
vaccinated with a unique live attenuated SIV [17]. They
revealed that animals inoculated with a persistent SIVΔnef
strain mounted potent ADCC activity, and that it was this
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sterilizing protection against SIVmac251 challenge. In this
context, our findings that CD4 and BST2 contributed to
ADCC enhancement warrant further investigations since
in SIV, Nef down-regulates both BST2 and CD4 [31,32].
Since 2G12 recognizes mannose residues on the ex-
terior domain of gp120 [27], the residual binding of this
Ab on BST2-depleted cells infected with the ΔNefΔVpu-
D368A Env virus could be an accumulative consequence
of carbohydrate modulations by Vpu and/or Nef and
of virus particle retention by the residual BST2 that
remained at the cell surface. In any case, regardless of
how the 2G12 epitope might be recognized on T cells
infected with the viruses used in our study, the key
message is that 2G12 binding is not dependent on CD4-
Env interactions, and that despite its efficient binding on
Env, 2G12 is still significantly less potent than A32 at
inducing ADCC. This observation was consistent with
those reported earlier using CEM.NKRCCR5 T cells
coated with recombinant Env or infected with HIV [18].
Conclusions
In summary, our study provides a further insight as to
how epitopes recognized by ADCC-mediating Abs can
be most efficiently accessible on target cells. This work
also unveils yet another mechanism by which HIV,
through its accessory proteins Nef and Vpu, can evade
the host’s immune defenses. Hence, by allowing for effi-
cient release of progeny virus particles and preventing
CD4 accumulation at the cell surface, HIV-1 ensures
that Env epitopes targeted by ADCC remain unexposed.
Therefore, inhibition of Vpu and Nef, could represent a




Phytohemagglutinin-L was purchased from Sigma-Aldrich
(St. Louis, MO, USA). The eFlour670 dye was from
eBioscience. Human recombinant interleukin-2 (IL-2) [33]
was obtained through the NIH AIDS Research and
Reference Reagent Program. Anti-GFP was acquired from
Invitrogen. Mouse anti-p24 mAb (Cat. # HB9725) was
isolated from the culture supernatant of hybridoma cells
from the American Type Culture Collection. PerCP-Cy
5.5-conjugated anti-human CD4, allophycocyanin (APC)-
conjugated anti-human Fc Ab, and AF647-conjugated
anti-IgG secondary Ab were from Biolegend. Anti-HIV
gp120 mAbs A32 and 2G12 were obtained through the
NIH AIDS Research and Reference Reagent Program from
Dr. James E. Robinson [34] and Dr. Hermann Katinger
[27], respectively. The A32 Fab was obtained from
Dr. Guido Ferrari and Dr. Barton Haynes (Center for
HIV-AIDS Vaccine Immunology, Duke University). Anti-Vpu and anti-BST2 rabbit sera were described previously
[35]. HIV-infected plasmas were obtained through the
Montreal Primary Infection cohort that is part of the
Fonds de Recherche du Québec-Santé (FRQ-S) AIDS Net-
work. Plasmas from HIV- and HCV- seronegative donors
were obtained through a cohort of healthy volunteers
maintained at the Institut de recherches cliniques de
Montréal (IRCM). Research protocols were approved by
the research ethics review board at the IRCM.
Plasmid and proviral DNA constructs
The vesicular stomatitis virus (VSV) glycoprotein G-ex-
pressing plasmid, pSVCMVin-VSV-G, was previously
described [35].
The infectious CCR5-tropic NL4.3.ADA.IRES.GFP wild-
type (WT), which contains all accessory proteins, and its
Vpu-deficient derivative (ΔVpu, U-) were generated as
described [36]. The WT construct was used to generate
various isogenic proviruses using standard molecular
biology techniques. The NL4.3.ADA.IRES.GFPΔNef (N-)
was created by introducing a frame-shift mutation at the
unique Xho1 site within the Nef coding region, thus, ge-
nerating a truncated inactive Nef protein of 38 amino-acid
residues. The isogenic NL4.3.ADA.IRES.GFP ΔNefΔVpu
(N-U-) combined the two mutations present in the ΔVpu
and ΔNef proviral constructs, while the NL4.3.ADA.IRES.
GFP ΔNefΔVpu-D368A Env (N-U-D368A) was generated
by introducing a substitution mutation (D/A) at position
368 of Env using Quickchange mutagenesis (Stratagene).
Production of VSVg-pseudotyped lentiviral vectors and
HIV-1 viruses
For lentiviral vector production, HEK293 T cells were
transfected with plasmid pLKO.1 (puromycin-resistant)
expressing shRNA targeting BST2 (Clone ID: TRCN00
00107018, from OpenBiosystem) or control shRNA
together with the packaging construct psPAX2 (a gift
from Dr. D. Trono at Swiss Institute of Technology) and
VSV-G expressing plasmid pSVCMVin-VSV-G using a
calcium phosphate precipitation method. Vectors were
purified by ultracentrifugation 48 h later [37].
For virus production, HEK 293 T cells were transfected
with appropriate proviruses and pSVCMVin-VSV-G using
the calcium phosphate method [35]. Viruses were har-
vested 48 h later [37] and titrated by MAGI assay as
described [38].
Preparation of CEM.NKR CD4+ T cell line depleted of
BST2
CEM.NKR cells were transduced by spin-inoculation [39]
using lentiviral vector particles containing shRNA tar-
geting BST2 or control shRNA. Forty-eight hours later,
puromycin was added and puromycin-resistant cells were
selected after 10 days. BST2 expression was determined
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pleted of BST2 were characterized functionally for viral
release 48 h post-infection with the CCR5-tropic NL4-3.
ADA.IRES.GFP WT or NL4-3.ADA.IRES.GFPΔVpu virus.
Jurkat T cell lines: phenotype, infection and assessment
of surface molecule expression by flow cytometry
Four different Jurkat T cell lines were used in this study.
Their phenotype for CD4 and BST2 expression as deter-
mined by flow cytometry is as follows. The first line, de-
rived from a Jurkat line that stably expresses the SV40
large T antigen [40], is negative for both CD4 and BST2
[41] and shall be referred to in the paper as CD4-/BST2-.
The second line, a derivative of the first one, expresses
high levels of CD4 upon stable transfection with a SV40
origin-containing CD4 expressor. This line is referred to
in the paper as CD4hi/BST2-. The third and fourth lines
of Jurkat are derivatives of the E6.1 clone from the ATCC.
The former expresses minimally CD4 and positive for
BST2 (CD4lo/BST2), while the latter expresses CD4 and
BST2 at relatively comparable levels (CD4+ /BST2+).
Preparation of primary effector/target cells and infection
of CD4+ T cells
Peripheral blood mononuclear cells (PBMC) were pre-
pared from whole blood of HIV- and HCV- seronegative
donors as described [39]. In certain experiments where
effector cells were destined to have no monocytes/macro-
phages, PBMC were cultured in serum-free RPMI 1640
(Wisent) for 2 h to remove monocytes/macrophages by
plastic-adherence. Non-adherent cells were recovered to
be used as effector cells. When effector cells were to con-
tain no NK cells, PBMC were depleted of NK cells using
CD56 microbeads (Miltenyi Biotec). Cell purity was
confirmed by flow-cytometry using anti-human CD14 or
anti-human CD56 Abs, respectively. In all cases, effector
cells to be used in ADCC assays were cultured overnight
in complete RPMI 1640 medium (10% FBS supplemented
with L-Glutamine, Pennicilin-streptomycin, and 100 U/mL
IL-2).
For HIV-infection of CD4+ T cells, activated primary
CD4+ T cells were spin-infected [39] as well as T cell
lines (CEM.NKR and Jurkat) with CCR5-tropic NL4.3.
ADA.IRES.GFP viruses at multiplicity of infection of
0.5-1 depending on cell types. Forty-eight hours post-
infection, T cells were analyzed by flow cytometry, when
appropriate, for CD4, BST2 and Env expression or for
ADCC activity.
Flow cytometry
CD4 staining was done as per manufacturer’s protocols.
For Env staining, infected cells were stained with anti-
human Env primary Abs (A32 or 2G12) or control IgG
for 30 min at 4°C, and then exposed to APC-conjugatedanti-human Fc secondary Ab (Biolegend). For Env stain-
ing analyses using human plasmas, target cells were
stained with diluted plasma (1:250 to 1:1000 dilutions)
from HIV-infected individuals or as control, with plas-
ma from healthy donors. Staining conditions were as
described for A32. Fluorescence signals were revealed
using AF647-conjugated anti-IgG secondary Ab. In
certain experiments where A32 binding specificity was
being evaluated, cells were pre-exposed to the A32 Fab
(3.8 μg/mL) for 30 min at room temperature (RT) prior
to the A32 incubation step.
BST2 staining was done as described using anti-rabbit
BST2 Ab or as a control, a rabbit pre-immune (PI)
serum [35].
Antibody-dependent cytotoxicity assay (ADCC)
50,000 target (T) cells, plated in 96-well V-bottom plates,
were exposed to A32 (1.4 μg/mL), 2G12 (1.4 μg/mL) or
human control IgG Ab for 30 min at RT. In certain exper-
iments, target cells were pre-incubated with the A32 Fab
for 30 min before adding A32. As an alternative source of
Abs, target cells were incubated with empirically-deter-
mined concentrations of plasmas (1:250–1:1000 dilutions)
from HIV-infected patients or from healthy donors
(as control). Effector cells, that had been labelled with
eFlour670 dye were mixed with target cells at effector:tar-
get ratios of 10:1 to 30:1. The cell mixtures were spun for
3 min at 400 × g and cultured for 4–4.5 h at 37°C. Subse-
quently, medium was removed by centrifugation, cells
were fixed in 1% PFA and analyzed on a CyAn ADP
analyzer for GFP expression. Percent of cell lysis was de-
termined as [(% GFP+ in the absence of effectors -% GFP+
in the presence of effector cells and test Ab)/% GFP+ in
the absence of effectors] × 100. Depending on analysis,
test Ab could be plasma (uninfected or infected), IgG,
2G12, A32 or A32 Fab + A32.
Viral particle release assay
BST2-expressing or BST2-depleted CEM.NKR CD4+ T
cells were infected for 48 h with CCR5-tropic NL4-3.
ADA.IRES.GFP WT or ΔVpu virus. Virions were purified
by ultracentrifugation [35]. Virions and cells were lysed in
RIPA-DOC buffer (10 mM Tris pH 7.2, 140 mM NaCl,
8 mM Na2HPO4, 2 mM NaH2PO4, 1% Nonidet-P40, 0.5%
sodium dodecyl sulfate, 1.2 mM deoxycholate), and West-
ern blotting was performed [35] using Abs specific for
Vpu, GFP or Gag (the anti-Gag Ab recognizes the precur-
sor p55 and the processed forms of Gag, including p24).
Statistical analyses
Unless otherwise stated, data are expressed as average ±
SEM. Statistical analyses of the data were done using
two-tailed, paired (when appropriate) Student’s t-tests.
P values of ≤ 0.05 were considered statistically significant:
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significant.Additional files
Additional file 1: Figure S1. Effect of BST2 depletion on HIV-1 envelope
expression profiles on infected CD4+ T cells. BST2 was depleted from CEM.
NKR CD4+ T cells as described in Methods. BST2-expressing (NT) and
BST2-depleted (SH) CEM.NKR T cells were infected with CCR5-tropic NL4.3.
ADA.IRES.GFP WT virus or derivatives lacking Vpu (U-), Nef (N-) or both
(N-U-). The N-U- D368A viral construct contains a mutation at residue 368 of
Env which prevents CD4-Env interactions. Forty-eight hours post-infection,
cells were stained with A32 (A) or 2G12 (B) Abs and analyzed for Env
expression by flow cytometry. Mock (M)-infected cells stained in parallel
were used as control. Shown next to the overlays are Env levels in MFI
obtained for gated GFP + infected cells from a representative analysis. The
histograms shown depict the average fold increase (+/− SD) in Env staining
relative to WT virus-infected cells in two experiments.
Additional file 2: Figure S2. Examining the relative contributions of
CD4 and BST2 in promoting Env staining by A32 or 2G12 Abs. Jurkat T
cell lines which vary in their expression of CD4 and BST2 (A) were
infected with NL4.3.ADA.IRES.GFP WT virus or derivatives lacking Vpu (U-),
Nef (N-) or both (N-U-) as described in Methods. Forty-eight hours later,
cells were stained for (B) CD4 and BST2 and for Env using (C) A32 or (D)
2G12 Abs, and analyzed for their expression by flow cytometry. Mock
(M)- infected cells stained in parallel were used as control. Indicated next
to the overlays (A, C and D) were expression levels shown in MFI for
infected T cells (GFP+) from a representative analysis. The histograms
(B) depict the percentage of CD4 or BST2 down-regulation in GFP-positive
cells relative to respective GFP-negative cells.
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